Roche acquires Irish biotech firm Inflazome for €380m
Roche paid an upfront payment of €380m to the Inflazome shareholders, and are also eligible to receive additional…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Sep 20
Roche paid an upfront payment of €380m to the Inflazome shareholders, and are also eligible to receive additional…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Sep 20
The deal will benefit Gilead with Trodelvy (sacituzumab govitecan-hziy), an advanced Trop-2 directed antibody-drug conjugate, developed by Immunomedics
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Sep 20
Takeda is expected to receive around $562m in an upfront payment, subject to customary legal and regulatory closing…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Aug 20
The sale of consumer health care business will further strengthen Takeda’s focus on five key business areas, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Aug 20
Kesimpta is indicated for relapsing forms of MS (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Aug 20
The acquisition will enable J&J’s pharmaceutical business Janssen to expand its operations in immune-mediated diseases and autoantibody-driven diseases
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Jul 20
DFC loan will be used to launch a new business unit, Kodak Pharmaceuticals, for the domestic production and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Jul 20
The proposed joint investment is aimed at the development of advanced technology for large-scale manufacture of active ingredients…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Jul 20
Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Jul 20
Along with the 49.9% stake, Gilead Sciences also received an exclusive option to acquire the remaining stake in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates